Perrigo Company plc

PRGO

Healthcare|Drug Manufacturers - Specialty & Generic|IE

$15.85

+0.14 (+0.89%)

DCF Value

$78.08

Cash / Share

$3.13

Financials

Financial Snapshot

Market Cap

$2.20B

Enterprise Value

$5.05B

Revenue (TTM)

$4.09B

Net Income (TTM)

-$1.77B

Cash & Investments

$436.6M

Net Cash

-$2.85B

Free Cash Flow (TTM)

$223.9M

Operating CF (TTM)

$296.3M

Debt/Equity

1.35

Cash Runway & Burn Rate

Company is cash-flow positive.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Cash & Investments	$622.3M	$678.7M	$551.1M	$354.3M	$631.5M	$1.86B	$600.7M	$751.3M	$558.8M	$531.6M	$436.6M
Operating Cash Flow	$654.9M	$698.9M	$593.0M	$387.8M	$636.2M	$156.3M	$307.3M	$405.5M	$362.9M	$238.5M	$296.3M
Free Cash Flow	$548.7M	$610.3M	$490.4M	$250.1M	$465.8M	$4.2M	$210.9M	$303.8M	$244.6M	$145.1M	$223.9M
Capital Expenditure	-$106.2M	-$88.6M	-$102.6M	-$137.7M	-$170.4M	-$152.1M	-$96.4M	-$101.7M	-$118.3M	-$93.4M	-$72.4M
Financing Cash Flow	-$268.7M	-$3.00B	-$571.9M	$1.8M	-$181.1M	-$178.7M	$421.6M	-$187.2M	-$611.0M	-$220.5M	-$572.0M

R&D Spending

R&D (TTM)

$92.0M

R&D Intensity

2.2%

R&D Growth vs Prior

-3.6%

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Revenue	$5.28B	$4.95B	$4.73B	$3.87B	$4.09B	$4.14B	$4.45B	$4.66B	$4.37B	$4.25B	$4.09B
R&D Expense	$184.0M	$167.7M	$218.6M	$119.2M	$121.7M	$122.0M	$123.1M	$122.5M	$112.2M	$95.4M	$92.0M
R&D % of Revenue	3.5%	3.4%	4.6%	3.1%	3.0%	2.9%	2.8%	2.6%	2.6%	2.2%	2.2%
SG&A	$1.21B	$1.15B	$1.13B	$1.10B	$1.11B	$1.11B	$1.21B	$1.27B	$1.11B	$526.5M	$381.6M

Income Statement

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Revenue	$5.28B	$4.95B	$4.73B	$3.87B	$4.09B	$4.14B	$4.45B	$4.66B	$4.37B	$4.25B	$4.09B
Cost of Revenue	$3.23B	$2.97B	$2.90B	$2.44B	$2.59B	$2.72B	$3.00B	$2.98B	$2.83B	$2.76B	$2.77B
Gross Profit	$2.05B	$1.98B	$1.83B	$1.43B	$1.49B	$1.42B	$1.46B	$1.68B	$1.54B	$1.49B	$1.32B
R&D	$184.0M	$167.7M	$218.6M	$119.2M	$121.7M	$122.0M	$123.1M	$122.5M	$112.2M	$95.4M	$92.0M
SG&A	$1.21B	$1.15B	$1.13B	$1.10B	$1.11B	$1.11B	$1.21B	$1.27B	$1.11B	$526.5M	$381.6M
Operating Income	-$2.00B	$598.2M	$236.5M	$174.7M	$265.2M	$410.4M	$78.9M	$151.9M	$112.9M	$343.3M	$165.5M
Interest Expense	$218.8M	$173.4M	$129.0M	$126.5M	$127.7M	$125.0M	$156.0M	$173.8M	$187.8M	$162.5M	$147.0M
Pretax Income	-$4.85B	$280.1M	$290.6M	$148.0M	$5.9M	$258.7M	-$139.1M	-$8.3M	-$80.7M	-$1.30B	-$1.65B
Net Income	-$4.01B	$119.6M	$131.0M	$146.1M	-$162.6M	-$68.9M	-$140.6M	-$12.7M	-$171.8M	-$1.43B	-$1.77B
EPS (Diluted)	-28.00	0.84	0.95	1.07	-1.19	-0.98	-0.97	-0.09	-1.25	-10.29	-12.77
EBITDA	-$4.18B	$1.14B	$906.0M	$662.0M	$518.4M	$695.9M	$355.5M	$525.0M	$433.0M	-$797.9M	-$1.11B
Shares Out. (M)	143.30	142.60	138.30	136.50	136.10	133.60	134.50	135.30	137.40	138.50	139.40

Balance Sheet

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Cash & Equivalents	$622.3M	$678.7M	$551.1M	$354.3M	$631.5M	$1.86B	$600.7M	$751.3M	$558.8M	$531.6M	$436.6M
Short-Term Investments	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Current Assets	$2.81B	$2.82B	$2.90B	$2.73B	$3.13B	$3.86B	$2.72B	$2.83B	$2.48B	$2.80B	$2.40B
Total Assets	$13.87B	$11.63B	$10.98B	$11.30B	$11.49B	$10.43B	$11.02B	$10.81B	$9.65B	$8.54B	$7.48B
Total Current Liabilities	$1.84B	$1.44B	$1.54B	$1.34B	$1.38B	$1.59B	$1.11B	$1.59B	$1.04B	$1.01B	$1.02B
Long-Term Debt	$5.22B	$3.27B	$3.05B	$3.37B	$3.53B	$2.92B	$4.07B	$3.63B	$3.58B	$3.74B	$3.28B
Total Liabilities	$7.91B	$5.46B	$5.32B	$5.50B	$5.83B	$5.27B	$6.18B	$6.04B	$5.33B	$5.60B	$5.04B
Stockholders' Equity	$5.96B	$6.17B	$5.67B	$5.80B	$5.66B	$5.15B	$4.84B	$4.77B	$4.32B	$2.94B	$2.44B
Retained Earnings	-$2.10B	-$1.98B	-$1.84B	-$1.70B	-$1.86B	-$1.93B	-$2.07B	-$2.08B	-$2.25B	-$3.68B	-$4.03B

Cash Flow Statement

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Operating Cash Flow	$654.9M	$698.9M	$593.0M	$387.8M	$636.2M	$156.3M	$307.3M	$405.5M	$362.9M	$238.5M	$296.3M
Capital Expenditure	-$106.2M	-$88.6M	-$102.6M	-$137.7M	-$170.4M	-$152.1M	-$96.4M	-$101.7M	-$118.3M	-$93.4M	-$72.4M
Free Cash Flow	$548.7M	$610.3M	$490.4M	$250.1M	$465.8M	$4.2M	$210.9M	$303.8M	$244.6M	$145.1M	$223.9M
Investing Cash Flow	-$175.0M	$2.34B	-$126.8M	-$596.1M	-$187.8M	$1.28B	-$1.96B	-$77.5M	$78.8M	-$75.4M	$285.1M
Financing Cash Flow	-$268.7M	-$3.00B	-$571.9M	$1.8M	-$181.1M	-$178.7M	$421.6M	-$187.2M	-$611.0M	-$220.5M	-$572.0M
Issuance of Stock	$8.3M	$700.0K	$1.3M	$900.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Repurchase of Stock	$0.00	-$191.5M	-$400.0M	$0.00	-$164.2M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Debt Issuance	-$174.2M	-$2.72B	-$58.3M	$124.5M	$149.9M	-$30.6M	$583.6M	-$30.2M	-$437.8M	-$34.8M	-$13.4M
Stock Based Comp.	$23.0M	$43.8M	$37.7M	$52.2M	$58.5M	$60.1M	$0.00	$68.8M	$64.4M	$0.00	$31.3M
Net Change in Cash	$204.5M	$56.4M	-$127.6M	-$196.8M	$287.2M	$1.23B	-$1.26B	$150.6M	-$192.5M	-$27.2M	$4.1M

Dilution Tracker

Shares Outstanding

139M

5-Year Share Growth

+1.8%

Stock Issuance (TTM)

$0.00

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Shares Out. (M)	143.30	142.60	138.30	136.50	136.10	133.60	134.50	135.30	137.40	138.50	139.40
Change vs Prior %	—	-0.5%	-3.0%	-1.3%	-0.3%	-1.8%	0.7%	0.6%	1.6%	0.8%	0.6%
Stock Issuance	$8.3M	$700.0K	$1.3M	$900.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Stock Repurchase	$0.00	-$191.5M	-$400.0M	$0.00	-$164.2M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Stock Based Comp.	$23.0M	$43.8M	$37.7M	$52.2M	$58.5M	$60.1M	$0.00	$68.8M	$64.4M	$0.00	$31.3M

Margins & Profitability

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Gross Margin %	38.9%	40.0%	38.7%	37.0%	36.6%	34.2%	32.7%	36.1%	35.3%	35.1%	32.3%
Operating Margin %	-37.9%	12.1%	5.0%	4.5%	6.5%	9.9%	1.8%	3.3%	2.6%	8.1%	4.0%
Net Margin %	-76.0%	2.4%	2.8%	3.8%	-4.0%	-1.7%	-3.2%	-0.3%	-3.9%	-33.5%	-43.3%
EBITDA Margin %	-79.2%	23.0%	19.1%	17.1%	12.7%	16.8%	8.0%	11.3%	9.9%	-18.8%	-27.0%
FCF Margin %	10.4%	12.3%	10.4%	6.5%	11.4%	0.1%	4.7%	6.5%	5.6%	3.4%	5.5%
ROE %	-67.4%	1.9%	2.3%	2.5%	-2.9%	-1.3%	-2.9%	-0.3%	-4.0%	-48.6%	-68.1%
ROA %	-28.9%	1.0%	1.2%	1.3%	-1.4%	-0.7%	-1.3%	-0.1%	-1.8%	-16.7%	-23.6%
ROIC %	-13.1%	2.5%	1.1%	1.8%	2.6%	-2.2%	0.7%	0.8%	1.3%	4.5%	2.6%
R&D / Revenue %	3.5%	3.4%	4.6%	3.1%	3.0%	2.9%	2.8%	2.6%	2.6%	2.2%	2.2%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0.0%	-6.3%	-4.3%	-18.2%	5.6%	1.2%	7.6%	4.6%	-6.1%	-2.8%
Gross Profit	0.0%	-3.5%	-7.5%	-21.7%	4.3%	-5.3%	2.8%	15.5%	-8.2%	-3.1%
Operating Income	0.0%	129.9%	-60.5%	-26.1%	51.8%	54.8%	-80.8%	92.5%	-25.7%	204.1%
Net Income	0.0%	103.0%	9.5%	11.5%	-211.3%	57.6%	-104.1%	91.0%	-1252.8%	-729.7%
EPS (Diluted)	0.0%	103.0%	13.1%	12.6%	-211.2%	17.6%	1.0%	90.3%	-1231.2%	-723.2%
Operating Cash Flow	0.0%	6.7%	-15.2%	-34.6%	64.1%	-75.4%	96.6%	32.0%	-10.5%	-34.3%
Free Cash Flow	0.0%	11.2%	-19.6%	-49.0%	86.2%	-99.1%	4921.4%	44.0%	-19.5%	-40.7%
R&D Expense	0.0%	-8.9%	30.4%	-45.5%	2.1%	0.2%	0.9%	-0.5%	-8.4%	-15.0%
SG&A Expense	0.0%	-4.9%	-1.8%	-2.5%	1.1%	0.2%	8.9%	5.3%	-12.7%	-52.7%
Total Assets	0.0%	-16.2%	-5.6%	2.9%	1.7%	-9.3%	5.7%	-1.9%	-10.7%	-11.5%
Book Value / Share	0.0%	4.3%	-5.1%	3.8%	-2.6%	-7.2%	-6.6%	-2.1%	-10.8%	-32.6%
Debt	0.0%	-42.4%	-3.0%	3.9%	10.6%	-0.9%	17.1%	-5.8%	-11.2%	9.7%
Diluted Shares	0.0%	-0.5%	-3.0%	-1.3%	-0.3%	-1.8%	0.7%	0.6%	1.6%	0.8%

Valuation

P/E (TTM)At Loss

10Y Low / Med / High40.79 / 48.28 / 103.76

P/S0.54

10Y Low / Med / High0.45 / 1.26 / 2.51

P/B0.91

10Y Low / Med / High0.66 / 1.01 / 2.01

EV/EBITDAAt Loss

10Y Low / Med / High8.86 / 15.17 / 23.37

EV/Revenue1.23

10Y Low / Med / High1.26 / 1.87 / 3.24

P/FCF9.82

10Y Low / Med / High10.89 / 20.32 / 1237.39

Intrinsic Value Models (per share)

DCF Value

$78.08

Cash / Share

$3.13

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
P/E Ratio	-2.97	103.76	40.79	48.28	-37.58	-39.69	-35.14	-342.71	-20.57	-1.35	-1.24
P/S Ratio	2.26	2.51	1.13	1.82	1.49	1.26	1.03	0.94	0.81	0.45	0.54
P/B Ratio	2.00	2.01	0.94	1.21	1.08	1.01	0.95	0.91	0.82	0.66	0.91
EV/EBITDA	-4.09	13.25	8.86	15.17	17.71	10.10	23.37	14.62	15.22	-6.72	-4.56
EV/Revenue	3.24	3.05	1.70	2.59	2.25	1.70	1.87	1.65	1.51	1.26	1.23

Analyst Estimates & Quality

Altman Z-Score

-0.39

Distress

Piotroski F-Score

Moderate

Forward Estimates (consensus)

Metric	FY2026	FY2027	FY2028
Revenue	$3.99B	$3.90B	$3.79B
Net Income	$311.0M	$322.4M	$326.8M
EPS	$2.29	$2.31	$2.37
# Analysts (EPS)	2	3	1

Dividends

Dividend/Share (TTM)

$1.16

Dividend Yield

7.32%

Frequency

Quarterly

Next Payment

Dec 15, 2026

Recent Payments

Ex-Date	Pay Date	Amount	Frequency
Nov 27, 2026	Dec 15, 2026	$0.29	Quarterly
Aug 28, 2026	Sep 15, 2026	$0.29	Quarterly
May 29, 2026	Jun 16, 2026	$0.29	Quarterly
Mar 2, 2026	Mar 24, 2026	$0.29	Quarterly
Nov 28, 2025	Dec 16, 2025	$0.29	Quarterly
Aug 29, 2025	Sep 16, 2025	$0.29	Quarterly
May 30, 2025	Jun 17, 2025	$0.29	Quarterly
Mar 7, 2025	Mar 25, 2025	$0.29	Quarterly
Nov 29, 2024	Dec 17, 2024	$0.28	Quarterly
Aug 30, 2024	Sep 17, 2024	$0.28	Quarterly
May 31, 2024	Jun 18, 2024	$0.28	Quarterly
Mar 7, 2024	Mar 26, 2024	$0.28	Quarterly
Nov 30, 2023	Dec 19, 2023	$0.27	Quarterly
Aug 31, 2023	Sep 19, 2023	$0.27	Quarterly
Jun 1, 2023	Jun 20, 2023	$0.27	Quarterly
Mar 9, 2023	Mar 28, 2023	$0.27	Quarterly
Dec 1, 2022	Dec 20, 2022	$0.26	Quarterly
Sep 1, 2022	Sep 20, 2022	$0.26	Quarterly
Jun 2, 2022	Jun 21, 2022	$0.26	Quarterly
Feb 25, 2022	Mar 17, 2022	$0.26	Quarterly

Revenue Segments

By Product

Segment	2020	2021	2022	2023	2024	2025
Consumer Self-Care Americas	$2.69B	$2.69B	$2.93B	$2.96B	$2.69B	$2.59B
Consumer Self-Care International	$1.40B	$1.45B	$1.53B	$1.69B	$1.68B	$1.67B
RX Pharmaceuticals	$975.1M	—	—	—	—	—

By Geography

Segment	2020	2021	2022	2023	2024	2025
Europe	$1.35B	$1.39B	$1.47B	$1.62B	$1.60B	$1.62B
IRELAND	$29.8M	$23.7M	$29.3M	$40.8M	$39.6M	$42.1M
Other Geographical Areas	$271.6M	$179.8M	$107.3M	$116.3M	$119.5M	$96.7M
UNITED STATES	$3.44B	$2.57B	$2.87B	$2.92B	$2.65B	$2.54B